Muhammad Waqas, MD
Advanced Heart Failure and Transplant Cardiology · Little Rock, ARNPI 1609060334
Payments from drug & device makers
Across 843 payments — averaging $189.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$45K
- United Therapeutics Corporation$44K
- Medtronic$34K
- Abiomed$12K
- Novartis$11K
- Actelion Pharmaceuticals US, Inc.$10K
- plus $5K from 25 others
What the payments were for
- Consulting fees$13,50313%
- Speaking & faculty fees$61,80160%
- Travel & lodging$10,56210%
- Food & beverage$16,25216%
- Education$2910%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 63 | $44,750 |
| United Therapeutics Corporation | 104 | $43,837 |
| Medtronic(3 entities) | 48 | $34,288 |
| Abiomed | 102 | $11,690 |
| Novartis | 134 | $10,508 |
| Actelion Pharmaceuticals US, Inc. | 200 | $9,707 |
| Abbott | 45 | $2,045 |
| AstraZeneca | 50 | $1,225 |
| Merck | 25 | $405 |
| Pfizer | 18 | $392 |
| Akcea Therapeutics, Inc. | 6 | $149 |
| E.r. Squibb & Sons, L.L.C. | 8 | $130 |
| Getinge USA Sales, LLC | 1 | $125 |
| Cvrx, Inc. | 4 | $92 |
| Amgen | 5 | $71 |
| Lexicon Pharmaceuticals, Inc. | 4 | $70 |
| Irhythm Technologies, Inc. | 4 | $61 |
| Alnylam Pharmaceuticals Inc. | 3 | $50 |
| Johnson & Johnson(2 entities) | 4 | $47 |
| Boehringer Ingelheim | 3 | $41 |
| Sandoz | 1 | $38 |
| Boston Scientific | 2 | $33 |
| Silk Road Medical, Inc. | 1 | $27 |
| Atricure, Inc. | 1 | $20 |
| Solventum Corporation | 1 | $18 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $18 |
| Philips North America LLC | 1 | $16 |
| Bridgebio Pharma, Inc. | 1 | $15 |
| Novo Nordisk | 1 | $14 |
| CMP Pharma, Inc. | 1 | $14 |
| Scpharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Adempas$20,271
- ORENITRAM$20,187
- TYVASO$15,834
- REMODULIN$12,764
- Impella$10,332
- ENTRESTO$8,697
- OPSUMIT$6,500
- NONE$3,190
- UPTRAVI$725
- HeartMate 3 Left Ventricular Dev$420
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$245
- HeartWare HVAD$219
- MitraClip$146
- CentriMag$130
- Mitra Clip system$129
- CARDIOHELP$125
- HeartMate 3 Left Ventricular Assist Device$120
- VYNDAQEL$110
How this compares
Too few advanced heart failure and transplant cardiology providers in Arkansasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 691 | $8,726,838 |
| UptraviSelexipag | 144 | $3,160,285 |
| AdempasRiociguat | 198 | $2,708,591 |
| VyndamaxTafamidis | 109 | $2,657,231 |
| Tyvaso DpiTreprostinil | 83 | $1,908,813 |
| Orenitram ErTreprostinil Diolamine | 107 | $680,929 |
| FarxigaDapagliflozin Propanediol | 686 | $483,007 |
| EntrestoSacubitril/Valsartan | 442 | $384,679 |
| Ambrisentan | 110 | $320,417 |
| WinrevairSotatercept-Csrk | 17 | $233,838 |
| OpsynviMacitentan/Tadalafil | 15 | $191,153 |
| JardianceEmpagliflozin | 169 | $120,137 |
| Tadalafil | 311 | $101,365 |
| CorlanorIvabradine Hcl | 43 | $41,121 |
| AdcircaTadalafil | 12 | $34,477 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi, Opsynvi | $9,707 | $12,078,276850 claims |
| BayerAdempas | $44,750 | $2,708,591198 claims |
| PfizerVyndamax, Eliquis | $392 | $2,673,255137 claims |
| AstraZenecaFarxiga | $1,225 | $483,007686 claims |
| NovartisEntresto | $10,508 | $384,679442 claims |
| MerckWinrevair | $405 | $233,83817 claims |
| Boehringer IngelheimJardiance | $41 | $120,137169 claims |
| AmgenCorlanor | $71 | $41,12143 claims |
| United Therapeutics CorporationAdcirca | $43,837 | $34,47712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Arkansason file to place this against a meaningful peer group, so we don't.
Other advanced heart failure and transplant cardiology in Little Rock
- Patrick CampbellLittle Rock$186K
- Jennifer CookLittle Rock$85K
- Linnea LebaronLittle Rock$13K
- Kruti PatelLittle Rock$11K
- Steven HutchinsLittle Rock$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.